ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Top-Line Results Released from Huntington’s Disease Study americanpharmaceuticalreview
September 27, 2020Vaccinex announced topline results from the early manifest treatment arm (Cohort B1, N=179) of the Phase 2 double-blind, placebo-controlled SIGNAL trial of its lead clinical candidate, pepinemab, in patients with early manifest and ... -
Vaccinex, Merck Collaborate on Keytruda Combo contractpharma
September 18, 2020?Vaccinex Inc., a clinical-stage biotechnology company, has entered into a clinical collaboration agreement with Merck through a subsidiary, to evaluate the combination of Vaccinex’s investigational SEMA4D inhibitor, pepinemab, and Merck’s anti-PD-1 ...
Pharma Sources Insight January 2025
